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RChoice of Appropriate Endpoints
for a Balloon Versus Stent Trial
The recent paper by Latib et al. (1) compared the efficacy of a
paclitaxel-eluting balloon (PEB) with that of a paclitaxel-eluting
stent (PES) at preventing restenosis after percutaneous coronary
intervention in coronary arteries 2.8 mm in diameter. The
prespecified primary endpoint was in-stent, or in-balloon, angio-
graphic late lumen loss (LLL). Although the sample size was based
on a noninferiority hypothesis, the authors found that the PEB was
superior to the PES “in suppressing neointimal proliferation.” The
implication of this finding was that the PEB may be a better
revascularization option than PES.
LLL is an appropriate surrogate endpoint for the comparison of
antirestenotic efficacy of different drug-eluting stents in which the
increase in lumen diameter achieved in the index procedure is
similar. Unfortunately, the current study compares “apples with
oranges.” LLL is not an appropriate endpoint for a comparison of
a balloon and a stent procedure because, although LLL is greater
with a stenting procedure, the acute gain with stenting is greater
(1.37  0.31 mm vs. 0.96  0.30 mm; p  0.001). This finding
more than offsets the LLL so that luminal diameter at follow-up
is significantly larger with stenting (1–3). In the current study, the
minimal lumen diameter at 6 months for PES (1.68  0.51 mm)
was superior to PEB (1.48  0.41 mm) (p  0.006). Luminal
diameter (or radius), but not LLL, is a major parameter defined by
Poiseuille’s equation contributing directly to lesion hemodynamic
significance. These data do not support the contention that PEB
are superior to PES in the treatment of small coronary vessel
disease.
Furthermore, when comparing balloon- and stent-based treat-
ments, differences in LLL do not indicate differences in suppres-
sion of intimal hyperplasia. The mechanisms of restenosis differ
between groups. Although in-stent restenosis is a process of
smooth muscle cell migration and proliferation (4), restenosis after
balloon angioplasty is a more complex combination of early vessel
recoil and later negative remodeling, and to a lesser extent cell
proliferation (5). For these reasons, differences in LLL cannot be
attributed, as the authors do, to differences in efficacy in suppress-
ing intimal hyperplasia.
Although this study provides insights into the relative efficacy of
balloons and stents coated with paclitaxel, larger studies with
newer antiproliferative drugs in the stent arm, and more appropri-
ate angiographic endpoints, are still needed.
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Paclitaxel-Eluting Balloons
for Small-Vessel Disease
We read with great interest the study by Latib et al. (1) suggesting
that treatment of small-vessel disease (SVD) with paclitaxel-
eluting balloons was associated with less angiographic late loss and
rates of revascularization similar to paclitaxel-eluting stents (PES).
The study is of major clinical interest because there is scarce
information on the value of paclitaxel-eluting balloons in complex
de novo lesions, as those in SVD (2). However, late lumen loss
may be misleading as a primary endpoint when these inherently
different technologies are compared. Indeed, as illustrated by the
classical dictum “the more you gain, the more you lose” (3), balloon
therapy is systematically associated with a lower late loss, as a result
of its lower acute gain, compared with stents (4). Late loss is also
significantly related to vessel size, which, in this study, was
significantly smaller in the drug-eluting balloon (DEB) arm.
Therefore, in this situation, most investigators would favor the use
of other angiographic endpoints (namely, percent diameter steno-
sis or even minimal lumen diameter) at follow-up as surrogate
markers of efficacy because they are relatively independent from the
acute gain. Moreover, these late angiographic findings are more
closely associated with clinical endpoints (as target lesion revascu-
larization) than the mechanistically oriented late loss angiographic
parameter. The problem is that in the study by Latib et al. (1), both
minimal lumen diameter (1.68  0.51 mm vs. 1.48  0.41 mm;
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April 30, 2013:1831–4p  0.006) and diameter stenosis (26.69  20.38% vs. 32.31 
16.66%; p  0.06) at follow-up were better in the PES arm in the
“in-stent/balloon” analysis. Interestingly, these differences were not
detected in the “in-segment” analysis, suggesting the possibility of an
“edge phenomenon” after PES. Although not powered for clinical
events, the current study was large, timely, and nicely executed, and it
provides novel insights clearly supporting the value of DEB in patients
with SVD. Nevertheless, further studies are warranted to demonstrate
that DEB outperform PES, or are equivalent to second-generation
drug-eluting stents, before they would be widely adopted in this
challenging anatomic scenario (5,6).
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Reply
We thank Dr. White and colleagues and Dr. Alfonso and colleagues
for their interest in the BELLO (Balloon Elution and Late Loss
Optimization) study, which is to date the largest randomized trial to
compare drug-eluting balloons (DEB) with drug-eluting stents in de
novo small-vessel disease (1). We agree that there is an intrinsic
methodological weakness in comparing late loss with a device known
to produce a large immediate gain (stent) versus a device producing a
smaller initial gain (balloon) and therefore a lower late loss. This
situation has been demonstrated historically in the seminal studies of
stent versus balloon angioplasty (2,3), in which the late loss after
balloon angioplasty was about one-half of the late loss with a
bare-metal stent (about 0.3 mm vs. 0.6 mm). In our study, we face a
similar situation but with a difference in the fourth magnitude. This
finding cannot be dismissed by the simple statement that the “lower
you gain, the less you lose.” The fact that the late loss after DEB was4 times lower than after drug-eluting stents suggests, as expected, that
other mechanisms (the drug on the balloon) are in action to lower the
percentage of late loss compared with the small gain. This fact is
further supported by the lack of difference in binary restenosis
numerically and statistically.
Furthermore, we would like to take the opportunity to highlight
the absolute value of late loss after DEB in BELLO (0.08 0.38 mm).
This value is considerably lower than the values seen with competitor
DEBs in de novo disease: 0.32  0.56 mm overall and 0.18  0.38
mm for DEB only in the PEPCAD I (Paclitaxel-Eluting PTCA-
Balloon to Treat Small Vessel) study (4) or the 0.38  0.39 mm
(personal communication, January 2013, from Eurocor GmbH) result
found in the Valentines Trial II. We want to take the opportunity in
this letter to reaffirm that we are not claiming superiority of a balloon
procedure compared with a drug-eluting stent procedure regarding
final and follow-up lumen dimensions. Instead, our goal is to provide
data supporting the possibility of using an alternative procedure
(DEB) in situations in which stenting may not be considered ideal.
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Potential Impact of Concomitant
Valvular Lesions and Coronary
Artery Bypass Surgery on
Outcome in Low-Gradient
Severe Aortic Stenosis With
Preserved Ejection Fraction
We read with interest the study by Clavel et al. (1). The investigators
sought to compare outcomes among 3 groups of patients: those
with the syndrome of paradoxical low-flow, low-gradient (LF/LG)
